• Retina/Vitreous

    This prospective case series included 20 eyes treated with intravitreal bevacizumab (1.25 mg). At 12 months, 90 percent of eyes showed visual improvement of two lines or more and 70 percent of eyes showed visual improvement of three lines or more on ETDRS chart. Complete resolution of fluorescein leakage was demonstrated in 95 percent of eyes. Visual improvement occurred, for the most part, in the first three months of follow-up, during the period of the three scheduled monthly injections. A separate retrospective study in this month's edition also showed good, long-term results in 63 patients. At one year, 40 percent of patients' attained significant visual improvement (equal to or better than three lines) and 51 percent had a BCVA of 20/40 or better.